BRIEF-Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

Reuters
Nov 05
BRIEF-<a href="https://laohu8.com/S/ZAILF">Zai Lab</a> Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

Nov 5 (Reuters) - Zai Lab Ltd 9688.HK:

  • UPDATE ON AMGEN'S BEMARITUZUMAB PHASE 1B/3 FORTITUDE-102 STUDY

  • AMGEN STOPS PHASE 1B/3 TRIAL FOR INADEQUATE EFFICACY

Further company coverage: 9688.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10